Pi Therapeutics

company

About

Pi Therapeutics is a Cancer treatment company

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$19.70M
Industries
Biotechnology
Founded date
Jan 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$19.70M
Pi Therapeutics has raised a total of $19.70M in funding over 2 rounds. Their latest funding was raised on May 29, 2019 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 29, 2019 Series B $19.70M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Pi Therapeutics is funded by 1 investors. CBG Asset Management are the most recent investors.
Investor Name Lead Investor Funding Round
CBG Asset Management Series B